Platform Ingredient Atlas

The Platform Ingredient Atlas provides the standardized reference documentation for every ingredient incorporated within the SIRIAM Platform.

Each ingredient is described only once throughout the Handbook.

Regional formulations should refer to this chapter rather than repeating ingredient descriptions.

The atlas serves four primary purposes:

future platform development.

The atlas does not evaluate clinical efficacy.

Instead, it documents the intended architectural role of each ingredient within the SIRIAM formulation system.

• pharmaceutical standardization;
• formulation consistency;
• documentation of design rationale;

Every ingredient follows the same standardized reference format.

Ingredient Name

Classification

Vehicle Component

Structural Component

Functional Component

Regional Signature Component

Technical Component

(Multiple classifications may apply.)

Platform Role

Defines the principal architectural function of the ingredient within the SIRIAM Platform.

Current Platform Use

Lists the formulations in which the ingredient is currently incorporated.

Pharmaceutical Considerations

Documents relevant formulation characteristics including compatibility, stability and processing requirements.

Technical Notes

Preparation observations.

Storage considerations.

Manufacturing remarks.

Development Status

Development

Validated

Under Review

Retired

Professional Review Notes

Reserved for pharmaceutical review.

This structure will remain identical for every ingredient.

INGREDIENT SHEET 18-001

Magnesium Chloride

Classification

Functional Component

Regional Signature Component

Platform Role

Magnesium chloride is incorporated as a Functional Component within selected SIRIAM formulations.

Its inclusion is intended to support the overall formulation architecture where regional design considerations justify its use.

Within the platform, magnesium chloride is not regarded as a universal ingredient but as a formulation component whose incorporation depends on the specific Regional Signature Matrix.

Current Platform Use

Current development formulations include magnesium chloride in selected regional products.

The ingredient is not presently incorporated throughout the entire platform.

Future inclusion remains subject to ongoing pharmaceutical and clinical evaluation.

Regional Preference

Magnesium chloride is primarily considered for formulations in which regional design favours its inclusion.

Current platform development suggests stronger suitability for specific transition and trunk-oriented formulations than for universal application.

Pharmaceutical Considerations

Magnesium chloride is highly water soluble.

During formulation development particular attention should be given to:

long-term homogeneity.

Changes in concentration may influence formulation texture and therefore require technical validation.

Manufacturing Notes

Recommended incorporation:

verification of homogeneous dispersion.

The final production sequence shall be confirmed during pharmaceutical validation.

Packaging Considerations

The ingredient should remain compatible with:

acceptable storage stability.

Development Status

Under Professional Review

Current development indicates satisfactory pharmaceutical feasibility.

Final concentration has not yet been fixed within the Master Formula.

Future Development

Future optimization may include:

removal from selected formulations if unnecessary.

Any modification should preserve Platform Consistency.

Related Platform Chapters

Chapter 12 — Structural Matrix

Chapter 13 — Functional Matrix

Chapter 15 — Ingredient Design Strategy

Chapter 17 — Regional Signature Design

Professional Review Notes

Pharmaceutical Review

☐ Verify aqueous phase compatibility.

☐ Evaluate viscosity effects.

☐ Confirm emulsion stability.

☐ Assess compatibility with Cosgard preservation system.

☐ Validate reproducibility between production batches.

Platform Review

☐ Confirm whether magnesium chloride remains a regional ingredient.

☐ Evaluate possible incorporation into additional formulations.

☐ Record all concentration adjustments within the Development Record.

Editor's Note

The inclusion of magnesium chloride within the SIRIAM Platform reflects the current formulation development strategy.

Its architectural position remains subject to future pharmaceutical optimization and clinical development.

No therapeutic claims are assigned to its presence within this Handbook.

Editorial Rules for Chapter 18 (Platform Standard PS-018)

From this point onward, every ingredient will be documented using this exact template, creating a uniform, searchable reference atlas.

Each ingredient will occupy one standardized sheet, regardless of how many formulations contain it. Regional product chapters will simply reference the relevant ingredient sheets instead of repeating descriptions.

Evidence Classification

• aqueous phase incorporation;
• emulsion stability;
• preservation compatibility;
• final viscosity;
• complete dissolution in aqueous phase;
• gradual incorporation before emulsification where appropriate;
• standardized 15 ml airless dispensers;
• repeated pump dispensing;
• concentration adjustment;
• regional expansion;
• regional reduction;